CRISPR-Cas9-mediated exon skipping as a cardioprotective strategy in Duchenne muscular dystrophy

被引：1
|
作者：
Wilton-Clark, Harry [1 ]
Yokota, Toshifumi [1 ]
机构：
[1] Univ Alberta, Dept Med Genet, Edmonton, AB, Canada
来源：
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT | 2023年 / 30卷
关键词：
D O I：
10.1016/j.omtm.2023.08.013
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：500 / 501
页数：2
相关论文
共 50 条
  • [21] Exon-skipping therapy for Duchenne muscular dystrophy
    Nakamura, Akinori
    Takeda, Shin'ichi
    LANCET, 2011, 378 (9791): : 546 - 547
  • [22] Exon-skipping advances for Duchenne muscular dystrophy
    Echevarria, Lucia
    Aupy, Philippine
    Goyenvalle, Aurelie
    HUMAN MOLECULAR GENETICS, 2018, 27 (R2) : R163 - R172
  • [23] Clinical trials of exon skipping in Duchenne muscular dystrophy
    Mendell, Jerry R.
    Sahenk, Zarife
    Rodino-Klapac, Louise R.
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (09): : 683 - 690
  • [24] Exon-skipping therapy for Duchenne muscular dystrophy
    Bhagavati, Satyakam
    LANCET, 2012, 379 (9811): : E10 - E10
  • [25] The Potential of Exon Skipping for Treatment for Duchenne Muscular Dystrophy
    Partridge, Terence
    JOURNAL OF CHILD NEUROLOGY, 2010, 25 (09) : 1165 - 1170
  • [26] Optimization of therapeutic antisense-mediated exon skipping for Duchenne muscular dystrophy
    Aartsma-Rus, Annemieke
    Heemskerk, Hans
    De Winter, Christa
    Janson, Anneke
    Van Ommen, Gert-Jan
    Van Deutekom, Judith
    HUMAN GENE THERAPY, 2007, 18 (10) : 983 - 984
  • [27] Development of Antisense-Mediated Exon Skipping as a Treatment for Duchenne Muscular Dystrophy
    Heemskerk, Hans
    de Winter, Christa L.
    van Ommen, Gert-Jan B.
    van Deutekom, Judith C. T.
    Aartsma-Rus, Annemieke
    OLIGONUCLEOTIDE THERAPEUTICS, 2009, 1175 : 71 - 79
  • [28] Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy
    Lim, Kenji Rowel Q.
    Yoon, Chantal
    Yokota, Toshifumi
    JOURNAL OF PERSONALIZED MEDICINE, 2018, 8 (04):
  • [29] CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy
    Mbakam, Cedric Happi
    Lamothe, Gabriel
    Tremblay, Guillaume
    Tremblay, Jacques P.
    NEUROTHERAPEUTICS, 2022, 19 (03) : 931 - 941
  • [30] CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy
    Cedric Happi Mbakam
    Gabriel Lamothe
    Guillaume Tremblay
    Jacques P. Tremblay
    Neurotherapeutics, 2022, 19 : 931 - 941
12345